• Japanese
  • Korean
  • Chinese
Cover Image

Diabetes, Metabolic Syndrome and Cardiovascular Disease

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Table of Contents

1. Overview

  • 1.1. Statement of Report
  • 1.2. About this Report
  • 1.3. Scope of the Report
  • 1.4. Methodology
  • 1.5. Executive Summary

2. Introduction

  • 2.1. Demographics of Diabetes
    • 2.1.1. Worldwide Diabetes
    • 2.1.2. U.S. Diabetes
  • 2.2. Economics of Diabetes
    • 2.2.1. Worldwide Costs of Diabetes
    • 2.2.2. Costs of Diabetes in the U.S.

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes

  • 3.1. Pre-Diabetes Syndrome
  • 3.2. Metabolic Syndrome
    • 3.2.1. Prevalence of Metabolic Syndrome
    • 3.2.2. Management of Metabolic Syndrome
    • 3.2.3. The Outlook for Metabolic Syndrome
    • 3.2.4. The Debate Regarding Metabolic Syndrome
  • 3.3. Diabetes and Inflammation
  • 3.4. Diagnosis of Diabetes Mellitus
  • 3.5. Progression of Diabetes
  • 3.6. Risk Factors and Diabetes
    • 3.6.1. Obesity
    • 3.6.2. Stress-Induced Hyperglycemia
  • 3.7. Complications and Co-Morbidities in Type 2 Diabetes
    • 3.7.1. Preventing Complications and Co-Morbidities in Diabetes
    • 3.7.2. Hypoglycemia Resulting from Treatment
  • 3.8. Cardiovascular Disease (CVD)
    • 3.8.1. CVD Facts
    • 3.8.2. Cardiac Care Therapeutics
      • 3.8.2.1. Anti-Hypertensive Drugs
      • 3.8.2.2. Cholesterol Management Drugs
      • 3.8.2.3. Anticoagulants
    • 3.8.3. CVD Diagnostics

4. Pharmaceutical Industry and the Anti-Diabetes Market

  • 4.1. The Worldwide Pharmaceutical Industry
    • 4.1.1. Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure
    • 4.1.2. Global Pharmaceutical Market
  • 4.2. Total Diabetes Drug Market Size and Growth
    • 4.2.1. Sales Forecast for the Global Anti-Diabetes Drug Market
  • 4.3. Diabetic Medications Overview
    • 4.3.1. Recent Trends in Diabetic Drug Usage
    • 4.3.2. Market Influence Factors

5. Non-Insulin Anti-Diabetes Products

  • 5.1. Anti-Diabetic Drug Therapy Overview
    • 5.1.1. Sulfonylureas
    • 5.1.2. Meglitinides
    • 5.1.3. Biguanides
    • 5.1.4. Thiazolidinediones (TZDs)
    • 5.1.5. α-Glucosidase Inhibitors
    • 5.1.6. Amylin Analog
    • 5.1.7. Glucagon-like Peptide (GLP-1) Analogs and Agonists/Incretin Mimetics
      • 5.1.7.1. Byetta (Exenatide)
      • 5.1.7.2. Bydureon (Exenatide LAR)
      • 5.1.7.3. Victoza (Liraglutide)
      • 5.1.7.4. Tanzeum (Albiglutide)
      • 5.1.7.5. Trulicity (Dulaglutide)
    • 5.1.8. DPP-IV Inhibitors
      • 5.1.8.1. Januvia (Sitagliptin)
      • 5.1.8.2. Onglyza (Saxagliptin)
      • 5.1.8.3. Tradjenta (Linagliptin)
      • 5.1.8.4. Galvus (Vildagliptin)
      • 5.1.8.5. Nesina (Alogliptin)
    • 5.1.9. SGLT-2 Inhibitors
      • 5.1.9.1. Invokana (Canagliflozin)
      • 5.1.9.2. Farxiga (Dapagliflozin)
      • 5.1.9.3. Jardiance (Empagliflozin)
      • 5.1.9.4. Suglat (Ipragliflozin)
      • 5.1.9.5. Lusefi (Luseogliflozin)
    • 5.1.10. Combination Therapy
      • 5.1.10.1. Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes Scarce
    • 5.1.11. Comparisons of the Anti-Diabetes Drugs
  • 5.2. Market Drivers and Trends
    • 5.2.1. Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs
  • 5.3. Non-Insulin Anti-Diabetes Products in the Pipeline
    • 5.3.1. Novel GLP-1 Agonists and Analogs
    • 5.3.2. Novel DPP-IV Inhibitors
    • 5.3.3. Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors
    • 5.3.4. Emerging Anti-Diabetes Targets and Drugs in the Pipeline
      • 5.3.4.1. Novel Approaches to Finding New Drug Targets

6. Insulin

  • 6.1. Insulin Markets
    • 6.1.1. Major Players and Market Share
    • 6.1.2. Patent Expirations
    • 6.1.3. Pathway for Insulin Biosimilars
      • 6.1.3.1. Regulatory Avenues for Biosimilar Approval
      • 6.1.3.2. Lantus Biosimilars
      • 6.1.3.3. Key Issues for Insulin Biosimilars
    • 6.1.4. Innovation Strategies
  • 6.2. Insulin Therapeutics
    • 6.2.1. Recommendations for Insulin Initiation and Administration
    • 6.2.2. Short-Acting Insulin
    • 6.2.3. Rapid-Acting Insulin
      • 6.2.3.1. Fast-Acting Insulins in Development
    • 6.2.4. Intermediate-Acting Insulin
    • 6.2.5. Long-Acting Insulin
    • 6.2.6. Insulin Mixtures
  • 6.3. Pipeline Insulins in Development
    • 6.3.1. Tresiba (Novo Nordisk)
    • 6.3.2. Ryzodeg (Novo Nordisk)
    • 6.3.3. Toujeo (Sanofi)
    • 6.3.4. BIOD-531 (Biodel)
    • 6.3.5. Xultophy (Novo Nordisk)
    • 6.3.6. LixiLan (Sanofi)
    • 6.3.7. rHUPH20 and Insulin (Halozyme)
    • 6.3.8. FIAsp (Novo Nordisk)
    • 6.3.9. BIOD-238, BIOD-250, and BIOD-351 (Biodel)
    • 6.3.10. InsuPatch and InsuPad (Insuline Medical)
  • 6.4. Non-Invasive Insulin Delivery
    • 6.4.1. Inhaled Insulin
      • 6.4.1.1. Afrezza
      • 6.4.1.2. Dance Pharmaceuticals and Aerogen (Dance-501)
      • 6.4.1.3. A Chronicle of Inhaled Insulins
    • 6.4.2. Oral Insulin
    • 6.4.3. Transdermal Insulin
  • 6.5. Barriers for Non-Injected Insulin
  • 6.6. Patient Potential for Non-Injected Insulin
  • 6.7. Insulin Delivery Devices
    • 6.7.1. Insulin Pens
    • 6.7.2. Injections Aids
      • 6.7.2.1. Automatic Injectors
      • 6.7.2.2. Syringe Magnifiers
      • 6.7.2.3. Injection Ports
    • 6.7.3. Insulin Jet Injectors
    • 6.7.4. Insulin Pumps
      • 6.7.4.1. External Insulin Pumps
      • 6.7.4.2. OneTouch Ping
      • 6.7.4.3. Accu-Chek Combo Insulin Pump System
      • 6.7.4.4. MiniMed Paradigm Real-Time Revel
      • 6.7.4.5. MiniMed 530G with Enlite
      • 6.7.4.6. Insulet Omnipod
      • 6.7.4.7. DANA IIS
      • 6.7.4.8. t:slim (Tandem Diabetes Care)
      • 6.7.4.9. Snap (Asante)
      • 6.7.4.10. Animas Vibe Pump/CGM
    • 6.7.5. Insulin Infusion Sets
    • 6.7.6. Insulin Patch Pumps in Development or Only Available Outside the U.S.
    • 6.7.7. Implantable Insulin Pumps
    • 6.7.8. Insulin Pump Market Share
    • 6.7.9. Drivers of Demand for Pumps
  • 6.8. Market Forecasts for Insulin Administration Technologies

7. Emerging Anti-Diabetes Technologies and Products

  • 7.1. Projections for the Anti-Diabetes Drug Market
  • 7.2. Artificial Pancreas
    • 7.2.1. MiniMed 530G System
    • 7.2.2. Animas Vibe System
    • 7.2.3. Next Generation Medtronic Artificial Pancreas Systems
    • 7.2.4. FDA's Artificial Pancreas Guidance Document
  • 7.3. Insulin-Producing Cells
    • 7.3.1. Gene Therapy
    • 7.3.2. Cell Therapy Companies for Diabetes
      • 7.3.2.1. ViaCyte (formerly Novocell, Inc.)
      • 7.3.2.2. Sernova
  • 7.4. Pancreatic Transplantation
    • 7.4.1. Candidates for Pancreatic Transplantation
      • 7.4.1.1. Pancreatic Organ Transplantation
      • 7.4.1.2. Allo-Islet Transplantation
      • 7.4.1.3. Implantation of Genetically Engineered b-Cells or Embryonic Stem Cells
    • 7.4.2. ADA Position on Pancreatic Transplantation
  • 7.5. Immune Modulators
  • 7.6. Gastric Bypass Surgery to Treat Type 2 Diabetes
  • 7.7. Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes
    • 7.7.1. Xenical (Roche)
    • 7.7.2. Qsymia (Vivus)
    • 7.7.3. Belviq (Arena Pharmaceuticals)
    • 7.7.4. Contrave (Orexigen Therapeutics)
    • 7.7.5. Anti-Obesity Drugs in Development
  • 7.8. Other Anti-Diabetic Therapy Drug Candidates
    • 7.8.1. Lipid Abnormalities
      • 7.8.1.1. New Cholesterol Guidelines
    • 7.8.2. High Blood Pressure
    • 7.8.3. Aspirin Therapy
  • 7.9. Drugs Used “Off-Label”
    • 7.9.1. Warfarin Sodium
  • 7.10. Insulin and Anti-Diabetes Drug Combinations
    • 7.10.1. Xultophy (Novo Nordisk)
    • 7.10.2. LixiLan (Sanofi)

8. Diagnosing Diabetes Using In Vitro Laboratory Tests

  • 8.1. Diagnostic Guidelines
  • 8.2. Diagnosis of Diabetes
    • 8.2.1. Fasting Plasma Glucose (FPG) Test
    • 8.2.2. Glucose Tolerance Test
    • 8.2.3. Test for Glycosylated Hemoglobin (HbA1c or A1c)
    • 8.2.4. Fructosamine
    • 8.2.5. Screening Tests for Diabetes-Related Complications
  • 8.3. Glucose Monitoring
    • 8.3.1. Overview of Market Segment
    • 8.3.2. Competitive Strategies
    • 8.3.3. Analyses of the Current Market Conditions, Competition and Product Mix
      • 8.3.3.1. First-Generation Monitors
      • 8.3.3.2. Second-Generation Monitors
      • 8.3.3.3. Third-Generation SMBG Technologies
      • 8.3.3.4. Product Overview
        • 8.3.3.4.1. LifeScan, Inc.
        • 8.3.3.4.2. Roche Diagnostics
        • 8.3.3.4.3. Bayer HealthCare
        • 8.3.3.4.4. Abbott Diabetes Care
        • 8.3.3.4.5. Other Players
    • 8.3.4. What are the Advantages of Using a Continuous Glucose-Monitoring Device
    • 8.3.5. Minimally-Invasive Continuous Glucose Monitors in Development
    • 8.3.6. Future of Non-Invasive Glucose Technology
    • 8.3.7. Lancets and Lancing Devices

9. Market Trends, Challenges and Strategic Options

  • 9.1. Overview
  • 9.2. Diabetes Drug Market Trends
    • 9.2.1. Overview
    • 9.2.2. Emergence of Therapeutics with Improved Administration Characteristics
      • 9.2.2.1. Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics
    • 9.2.3. Increasing Prevalence of Obesity
    • 9.2.4. Consumer Preference Drives Product Development in Invasive Technology Segment
  • 9.3. Diabetes Mellitus Market Challenges
    • 9.3.1. Overview
    • 9.3.2. Patent Expirations
    • 9.3.3. Market Prospects of Inhalable Insulin
  • 9.4. Strategic Options
    • 9.4.1. Developing Countries are Key Markets for Growth
    • 9.4.2. Consumer-Driven Marketing Campaigns
    • 9.4.3. Strategies for Successful New Product Launches
    • 9.4.4. Collaborations and Strategic Alliances
  • 9.5. FDA Guidelines for Developing Anti-Diabetic Drugs
  • 9.6. Recent Industry Activity

10. Company Profiles

  • 10.1. A. Menarini
  • 10.2. Abbott Laboratories
  • 10.3. Abbvie
  • 10.4. Amgen
  • 10.5. Amylin Pharmaceuticals (bought by Bristol-Myers Squibb)
  • 10.6. Animas (part of Johnson & Johnson)
  • 10.7. Asante
  • 10.8. Astellas Pharma, Inc.
  • 10.9. AstraZeneca Plc
  • 10.10. Bayer
  • 10.11. Becton, Dickinson and Company
  • 10.12. Biocon
  • 10.13. Biodel
  • 10.14. BodyMedia
  • 10.15. Boehringer Ingelheim
  • 10.16. Bristol Myers Squibb
  • 10.17. Cellnovo
  • 10.18. CeQur
  • 10.19. ConjuChem
  • 10.20. Daiichi Sankyo
  • 10.21. Dance Biopharm
  • 10.22. Debiotech
  • 10.23. DexCom
  • 10.24. Echo Therapeutics, Inc.
  • 10.25. Eli Lilly
  • 10.26. FIFTY50 Medical, Inc.
  • 10.27. Flamel Technologies
  • 10.28. Generex Biotechnology Corporation
  • 10.29. GlaxoSmithKline Plc
  • 10.30. Halozyme Therapeutics
  • 10.31. Insulet
  • 10.32. Insuline Medical Ltd.
  • 10.33. Intarcia Therapeutics, Inc.
  • 10.34. Janssen Research & Development
  • 10.35. Johnson & Johnson
  • 10.36. Kowa Pharmaceuticals
  • 10.37. Lexicon Pharmaceuticals
  • 10.38. MannKind Corporation
  • 10.39. Medipacs
  • 10.40. Medtronic
  • 10.41. Merck & Company, Inc.
  • 10.42. Mitsubishi Tanabe Pharma Corporation
  • 10.43. Novartis
  • 10.44. Novo Nordisk
  • 10.45. Oramed Pharmaceuticals
  • 10.46. Orexigen Therapeutics, Inc.
  • 10.47. Owen Mumford
  • 10.48. PhaseBio Pharmaceuticals
  • 10.49. Pfizer
  • 10.50. Prometheon Pharma
  • 10.51. Roche Diagnostics
  • 10.52. Sanofi-Aventis
  • 10.53. Sernova
  • 10.54. Smiths Medical
  • 10.55. SOOIL Development
  • 10.56. Taisho Pharmaceuticals
  • 10.57. Takeda
  • 10.58. Tandem Diabetes Care, Inc.
  • 10.59. Theracos, Inc.
  • 10.60. Transdermal Specialties, Inc.
  • 10.61. TransTech Pharma
  • 10.62. Valeritas
  • 10.63. Viacyte, Inc. (formerly Novocell)
  • 10.64. Vivus, Inc.
  • 10.65. Ypsomed Holding
  • 10.66. Zealand Pharma A/S

Appendix 1: The History of Insulin

INDEX OF FIGURES

  • Figure 2.1: Worldwide Diabetes Cases, 2013 and 2035
  • Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013
  • Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2012
  • Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012
  • Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013
  • Figure 2.6: Number of Deaths from Diabetes by Age in the U.S., 2010
  • Figure 2.7: Number of Diabetes Deaths by Race and Sex in the U.S., 2010
  • Figure 2.8: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD), 2013
  • Figure 2.9: How Diabetes Dollars are Spent in the U.S., 2012
  • Figure 2.10: Percent of Medical Condition-Specific Expenditures Associated with Diabetes, 2012
  • Figure 3.1: Maintenance of Normal Blood Sugar Levels
  • Figure 3.2: Prevalence of Self-Reported Obesity (BMI 330) Among U.S. Adults, 2012
  • Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2009-2010
  • Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 2009-2010
  • Figure 3.5: Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010
  • Figure 3.6: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S., 1997-2011
  • Figure 3.7: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, in the U.S., 1997-2011
  • Figure 3.8: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment, in the U.S., 1997-2011
  • Figure 3.9: Annual Death Rate of U.S. Population from Heart Disease, 1950-2009
  • Figure 3.10: Annual Death Rate of U.S. Population from Strokes, 1950-2009
  • Figure 3.11: Percentage Breakdown of Deaths Attributable to Cardiovascular Disease in the U.S., 2010
  • Figure 3.12: Death Rates from Cardiovascular Disease by State, 2010
  • Figure 3.13: Percentage of Obese Adults in the U.S., 1960-2010
  • Figure 3.14: Percentage of Obese Children and Adolescents in the U.S., 1971-2010
  • Figure 3.15: Number of Annual Prescriptions for Popular Cholesterol Drugs, 2007-2012
  • Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2010-2018
  • Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2010-2018
  • Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012
  • Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2013
  • Figure 5.1: Overview of GLP-1 and Blood Glucose
  • Figure 5.2: Overview of DPP-4 Inhibitors and Blood Glucose
  • Figure 5.3: SGLT-2 Inhibitor Mechanism of Action
  • Figure 5.4: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2013
  • Figure 5.5: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2013
  • Figure 6.1: Global Sales of Lantus, 2005-2013
  • Figure 6.2: Insulin Pump Market Share, 2013

INDEX OF TABLES

  • Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2013 and 2035
  • Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics (20-79 Years Age Group), \ 2013 and 2035
  • Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013
  • Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013
  • Table 2.5: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013
  • Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010
  • Table 2.7: Cost of Diagnosed Diabetes in the U.S., 2012
  • Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009
  • Table 2.9: Healthcare Utilization by Diabetic Patients, 2012
  • Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.2: Ethnic Specific Values for Waist Circumference in IDF's Metabolic Syndrome Criteria
  • Table 3.3: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.4: Additional Metabolic Criteria for Research
  • Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
  • Table 3.6: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
  • Table 3.7: Prevalence of Complications Among Patients with Diabetes
  • Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
  • Table 3.9: Major Causes of End-Stage Renal Disease
  • Table 3.10: Clinical Recommendations for Adults with Diabetes
  • Table 3.11: Laboratory Assessment of Diabetic Vascular Disease
  • Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
  • Table 3.13: Summary of Cardiovascular Diseases (CVDs)
  • Table 3.14: Death Rate from Cardiovascular Diseases by Country, 2008
  • Table 3.15: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S., 2010
  • Table 3.16: Selected Patent Expirations of Cardiac Care Drugs, 2012-2016
  • Table 3.17: Worldwide Market for Cardiac Care Therapeutics, 2010-2017
  • Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2010-2014
  • Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2013
  • Table 4.3: Leading Therapy Classes for R&D, 2014
  • Table 4.4: Leading Disease Indications for R&D, 2014
  • Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012
  • Table 4.6: Global Pharmaceutical Sales by Region and Country, 2012 and 2017, and CAGR 2008-2012 and 2013-2017
  • Table 4.7: World Pharmaceutical Sales Share by Region, 2012
  • Table 4.8: Leading Ten Therapeutic Classes by U.S. Sales, 2009-2013
  • Table 4.9: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2009-2013
  • Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Developed Market, 2017
  • Table 4.11: Estimated Leading Therapy Classes by Global Sales in the Pharmerging Market, 2017
  • Table 4.12: Top Selling Drugs in the U.S., 2013
  • Table 4.13: Top Selling Drugs Worldwide, 2013
  • Table 4.14: Top Ten Global Pharmaceutical Companies by Global Sales, 2013
  • Table 4.15: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2010-2018
  • Table 4.16: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2010-2018
  • Table 4.17: Anti-diabetic Therapy Markets, 2013
  • Table 4.18: The Leading Five Anti-Diabetics by Global Sales, 2013
  • Table 4.19: The Leading Five Anti-Diabetics by U.S. Sales, 2013
  • Table 4.20: Top Five Branded Anti-Diabetics by Prescription in the U.S., 2013
  • Table 4.21: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes
  • Table 4.22: Summary of Glucose-Lowering Interventions as Monotherapy
  • Table 5.1: Classes of Non-Insulin Hypoglycemic Agents
  • Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes in the U.S., 2014
  • Table 5.3: Relative Efficacy of Diabetes Drugs
  • Table 5.4: Fixed-Dose Oral Anti-Diabetes Drug Combinations
  • Table 5.5: Worldwide Anti-Diabetes Non-Insulin Drug Market, 2010-2018
  • Table 5.6: U.S. Anti-Diabetes Non-Insulin Drug Market, 2010-2018
  • Table 5.7: GLP-1 Agonist Pipeline: Selected Drugs in Development
  • Table 5.8: DPP-IV Inhibitor Pipeline: Selected Drugs in Development
  • Table 5.9: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development
  • Table 5.10: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs in Development
  • Table 5.11: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories
  • Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2013
  • Table 6.2: Worldwide Insulin Market, 2010-2018
  • Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2013
  • Table 6.4: U.S. Insulin Market, 2010-2018
  • Table 6.5: Key Drivers of the Type 2 Diabetes Insulin Market, 2013
  • Table 6.6: Worldwide Insulin Sales and Value Market Share by Company, 2013
  • Table 6.7: U.S. Insulin Sales and Value Market Share by Company, 2013
  • Table 6.8: Insulins on the U.S. Market
  • Table 6.9: Pharmacokinetics of Therapeutic Insulins on the U.S. Market
  • Table 6.10: Comparison of Recommendations from Existing Guidelines
  • Table 6.11: Pharmacokinetics of Short-Acting Insulins
  • Table 6.12: Pharmacokinetics of Rapid-Acting Insulins
  • Table 6.13: Pharmacokinetics of Intermediate-Acting Insulins
  • Table 6.14: Pharmacokinetics of Long-Acting Insulins
  • Table 6.15: Pharmacokinetics of Insulin Mixtures
  • Table 6.16: A Comparison of Existing Insulin Delivery Devices
  • Table 6.17: Insulin Pens
  • Table 6.18: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018
  • Table 6.19: Injection Aids
  • Table 6.20: Jet Injectors
  • Table 6.21: Control Averages by Treatment
  • Table 6.22: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
  • Table 6.23: Leading Insulin Pump Manufacturers
  • Table 6.24: Comparison of Current External Insulin Pumps on the Market
  • Table 6.25: Insulin Infusion Sets
  • Table 6.26: Worldwide Insulin Pump Market, 2013-2018
  • Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies
  • Table 7.2: Cells of the Pancreas
  • Table 7.3: Statin Recommendations for Designated Treatment Groups
  • Table 7.4: Statins Currently Available in the U.S.
  • Table 7.5: Statin Intensity Chart
  • Table 7.6: Summary of Non-Statin Cholesterol Lowering Drugs
  • Table 7.7: Suggested Pharmacological Treatment Agents for Hypertension
  • Table 8.1: Criteria for the Diagnosis of Diabetes
  • Table 8.2: Categories of Increased Risk for Diabetes (Pre-Diabetes)
  • Table 8.3: Normal Glucose Values-Fasting State
  • Table 8.4: Criteria for Testing for Diabetes in Asymptomatic Adults
  • Table 8.5: Criteria for Type 2 Diabetes in Asymptomatic Children
  • Table 8.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)
  • Table 8.7: Laboratory Assessment of Diabetic Vascular Disease
  • Table 8.8: Worldwide Glucose Self-Testing Market Sales (includes Meters, Strips and Lancets), 2012-2018
  • Table 8.9: Market for Glucose Self-Testing in the U.S. (includes Meters, Strips and Lancets), 2012-2018
  • Table 8.10: Market Share of U.S. Blood Glucose Self-Testing, 2013
  • Table 8.11: Lancet Characteristics
  • Table 9.1: BRIC countries, Percentage of GDP Spent on Healthcare, 2013
  • Table A1.1: Select Archived Press Release Excerpts
Show More
Pricing